Currently, MRK's 12-month EPS stands at $3.57, according to the most recent financial reports. Merck's earnings per share in 2025 was reported at $7.3, marking a rise from $6.76 in 2024. MRK recorded an EPS of -$1.72 for the quarterly period ending on Mar 31, 2026.
In 2025, Merck's earnings per share was $7.3, a rise of 8% from $6.76 in 2024. The quarterly earnings per share for the period ending Mar 31, 2026, was -$1.72, showing a 185.6% decline compared to the same quarter last year. The trailing twelve months EPS for MRK is $3.57 as of March 2026. Merck's full-year EPS for 2024 was $6.76, a 4,728.6% rise compared to the previous year.
Merck has recorded a decline in earnings per share of 185.6% in the past 12 months (YoY, quarterly). During the past three years, MRK registered an average yearly EPS growth of 8.4%. Merck had an average annual EPS growth of 21.2% in the last five years. Over the last decade, MRK had an average annual earnings per share growth of 16.5%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| BMY Bristol Myers Squibb Co | 15.32 | 178.7% | 5.3% | N/A |
| PFE Pfizer Inc | 19.15 | -3.5% | -37.4% | -3.7% |
| NVS Novartis AG | 21.22 | 21.8% | 31.2% | 15.2% |
| TEVA Teva Pharmaceutical Industries Ltd | 23.5 | 184.8% | N/A | N/A |
| AMGN Amgen Inc | 23.81 | 88.1% | 5.6% | 2.9% |
| ABT Abbott Laboratories | 24.47 | -51.4% | -1.8% | 8.2% |
| JNJ Johnson & Johnson | 26.49 | 90.6% | 17.7% | 14.8% |
| MRK Merck & Co Inc | 32.35 | 8% | 8.4% | 21.2% |
| LLY ELI LILLY & Co | 39.09 | 95.6% | 49.2% | 27.5% |
All data is based on quarterly TTM periods, unless otherwise specified.